PRECLINICAL TRIAL OF 4-AMINOPYRIDINE IN PATIENTS WITH CHRONIC SPINAL-CORD INJURY

被引：80

作者：

HAYES, KC

BLIGHT, AR

POTTER, PJ

ALLATT, RD

HSIEH, JTC

WOLFE, DL

LAM, S

HAMILTON, JT

机构：

[1] Department of Physical Medicine & Rehabilitation, Parkwood Hospital, London, ON, N6C 5JI

[2] Division of Neurosurgery, University of North Carolina, NC

[3] Department of Rehabilitation Nursing, Parkwood Hospital, London, ON

[4] Department of Pharmacology & Toxicology, The University of Western Ontario, London, ON

[5] The University of Western Ontario, London, ON

来源：

PARAPLEGIA | 1993年 / 31卷 / 04期

关键词：

SPINAL CORD INJURY; 4-AMINOPYRIDINE; DEMYELINATION; CONDUCTION BLOCK; PARALYSIS;

D O I：

10.1038/sc.1993.40

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

4-Aminopyridine (4-AP) is a K+ channel blocking agent that enhances nerve conduction through areas of demyelination by prolonging the duration of the action potential and increasing the safety factor for conduction. We have investigated the effects of 4-AP (24 mg total dose-intravenous) in 6 patients with spinal cord injury (3 complete, 3 incomplete) with the intent of overcoming central conduction block, or slowing, due to demyelination. Vital signs remained stable and only mild side effects were noted. The 3 patients with incomplete injuries all demonstrated enhanced volitional EMG interference patterns and one patient exhibited restored toe movements. The changes were reversed on drug washout. There were no changes in segmental reflex activities. These results are consistent with those obtained from 4-AP trials with animal models of spinal cord injury, showing modest therapeutic benefit attributable to enhanced central conduction.

引用

页码：216 / 224

页数：9

共 39 条

[11]

Bostock H., Sears T.A., Sherratt R.M., The effects of 4-aminopyridine and Tetraethylammonium ions on normal and demyelinated mammalian nerve fibres, J Physiol (Lond), 313, pp. 301-315, (1981)

[12]

Targ E.F., Kocsis JD (1985) 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve, Brain Res, 328, pp. 358-361

[13]

Blight A.R., Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury, Brain Res Bull, 22, pp. 47-52, (1989)

[14]

Blight A.R., Gruner J.A., Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats, J Neural Sci, 87, pp. 145-159, (1987)

[15]

Blight A.R., Toombs J.P., Bauer M.S., Widmer W.R., The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: A Phase I clinical trial, J Neurotrauma, 8, pp. 103-119, (1991)

[16]

Stefoski D., Davis F.A., Fitzsimmons W.E., Luskin S.S., Rush J., Parkhurst G.W., 4-Aminopyridine in multiple sclerosis: Prolonged administration, Neurology, 41, pp. 1344-1348, (1991)

[17]

Davis F.A., Stefoski D., Rush J., Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis, Ann Neural, 27, pp. 186-192, (1990)

[18]

Stefoski D., Davis F.A., Faut M., Schauf CL (1987) 4-Aminopyridine improves clinical signs in multiple sclerosis, Ann Neural, 21, pp. 71-77

[19]

Jones R.E., Heron J.R., Foster D.H., Snelgar R.S., Mason R.J., Effects of 4-aminopyridine in patients with multiple sclerosis, J Neurol Sci, 60, pp. 353-362, (1983)

[20]

Lundh H., Milsson O., Rosen I., Effects of 4-aminopyridine in myasthenia gravis, J Neurol Neitrnsurg Psychiat, 42, pp. 171-175, (1979)

← 1 2 3 4 →